Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
194 hedge funds and large institutions have $1.21B invested in Sage Therapeutics in 2023 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 83 increasing their positions, 44 reducing their positions, and 60 closing their positions.
128% more call options, than puts
Call options by funds: $19.5M | Put options by funds: $8.57M
89% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 44
7.65% more ownership
Funds ownership: 90.53% → 98.17% (+7.6%)
14% less funds holding
Funds holding: 225 → 194 (-31)
47% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 60
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
52% less capital invested
Capital invested by funds: $2.54B → $1.21B (-$1.33B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$149M |
| 2 |
State Street
Boston,
Massachusetts
|
+$60.1M |
| 3 |
SC
Samlyn Capital
New York
|
+$21.4M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$15.3M |
| 5 |
Morgan Stanley
New York
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$38.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$31.6M |
| 3 |
AG
Artal Group
Luxembourg
|
-$23.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$17.8M |
| 5 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$16.8M |
SAGE Hedge Fund Activity: Q3 2023 in Review
194 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2023, worth a combined $1.21B — down 52% from $2.54B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of SAGE and 32 opened new positions — a net loss of 28 holders — while 44 trimmed existing stakes and 83 added.
The largest buyer was RTW Investments, opening a new position worth an estimated $149M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $38.9M sold.
- 194 institutional investors held Sage Therapeutics (SAGE) as of Q3 2023, down from 225 in Q2 2023.
- Funds reported $1.21B of Sage Therapeutics stock for Q3 2023, down 52% quarter-over-quarter.
- 32 funds opened new Sage Therapeutics positions in Q3 2023 and 60 closed out, a net change of -28 holders.
- The largest Sage Therapeutics buyer in Q3 2023 was RTW Investments, an estimated $149M added.
- The largest Sage Therapeutics seller in Q3 2023 was Lord, Abbett & Co, an estimated $38.9M sold.
Based on aggregated 13F filings for Q3 2023.